<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572348</url>
  </required_header>
  <id_info>
    <org_study_id>UZG-U2018/01</org_study_id>
    <nct_id>NCT03572348</nct_id>
  </id_info>
  <brief_title>VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures.</brief_title>
  <acronym>VeSpAR</acronym>
  <official_title>VeSpAR: A Randomized Controlled Trial Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Urethral Strictures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to verify whether the surgical outcome of vessel-sparing anastomotic
      repair in isolated short bulbar urethral strictures is not inferior to the surgical outcome
      of transecting anastomotic repair. Furthermore, the investigators compare the functional
      outcome of both techniques verifying if there is less erectile dysfunction after
      vessel-sparing anastomotic repair than after transecting anastomotic repair.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled trial comparing vessel-sparing anastomotic repair (vsAR) and
      transecting anastomotic repair (tAR) in isolated short bulbar urethral strictures (maximum 3
      centimeter) for both surgical and functional outcome, to demonstrate that vsAR is not
      inferior to tAR regarding the surgical outcome, and to demonstrate a benefit for vsAR over
      tAR regarding postoperative erectile function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, interventional, multicentric, single-blinded, randomized, controlled, non-inferiority, phase II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients will be randomized using software in a 1:1 ratio in either the vessel-sparing group or the transecting group. Randomisation will be stratified per participating center and single blinded; double blindation is impossible as the surgeon has to know which technique to perform.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>FFS at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Failure-free survival at 24 months. Surgical failure is defined as urethroscopic evidence of stricture recurrence, impossible to pass with a 16Fr silicone urethral catheter, independent of whether the stricture is treated or not.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FFS at 3 and 12 months</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Failure-free survival at 3 and 12 months. Surgical failure is defined as urethroscopic evidence of stricture recurrence, impossible to pass with a 16Fr silicone urethral catheter, independent of whether the stricture is treated or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile function</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>Erectile function score assessed by the International Index of Erectile Function (IIEF-5) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejaculatory function</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>Ejaculatory function score assessed by the Male Sexual Health Questionnaire - Ejaculatory Dysfunction short form (MSHQ-EjD short form)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voiding function</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>Lower Urinary Tract symptoms assessed by the Peeling's voiding picture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Urinary Tract symptoms</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>Lower Urinary Tract symptoms assessed by the International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms module (ICIQ-MLUTS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary incontinence</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>Urinary incontinence assessed by the International Consultation on Incontinence Questionnaire - Urinary Incontinence short form (ICIQ-UI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum flow rate</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>Qmax assessed using uroflowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual urinary volumes</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>Residual urinary volumes examined by suprapubic ultrasonic measurement after voiding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ-5D-3L)</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>QoL scored by the EQ-5D-3L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ-VAS)</measure>
    <time_frame>3, 12, and 24 months</time_frame>
    <description>QoL scored by the EQ visual analogue scale (EQ-VAS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Urethral Stricture</condition>
  <condition>Surgery</condition>
  <condition>Urologic Diseases</condition>
  <arm_group>
    <arm_group_label>Transecting anastomotic repair (tAR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vessel-sparing anastomotic repair (vsAR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transecting anastomotic repair (tAR)</intervention_name>
    <description>Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.</description>
    <arm_group_label>Transecting anastomotic repair (tAR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vessel-sparing anastomotic repair (vsAR)</intervention_name>
    <description>Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.</description>
    <arm_group_label>Vessel-sparing anastomotic repair (vsAR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary signed written informed consent (according to the rules of Good Clinical
             Practice and national regulations)

          -  Male

          -  Age &gt;= 18 years

          -  Fit for operation, based on the surgeon's expert opinion

          -  Isolated short (=&lt; 3cm) bulbar urethral stricture confirmed by preoperative retrograde
             urethrography (RUG), voiding cysto-urethrography (VCUG), cystoscopy, ultrasonography
             or a combination of investigations

          -  Unique urethral stricture

          -  Urethral stricture =&lt; 3 cm

          -  Urethral stricture at the bulbar segment

          -  Patient declares that it will be possible for him to attend the follow-up consultation

        Exclusion Criteria:

          -  Absence of signed written informed consent

          -  Age &lt;18 years

          -  Female patients

          -  Transgender patients

          -  Patients unfit for operation

          -  Concomitant urethral strictures at other urethral locations (penile urethra,
             membranous urethra, prostatic urethra, bladder neck)

          -  Urethral strictures exceeding 3 cm

          -  A unique urethral stricture at other urethral locations (penile urethra, membranous
             urethra, prostatic urethra, bladder neck)

          -  Lichen Sclerosus related strictures

          -  Strictures after failed hypospadias repair

          -  Patients with neurogenic bladder

          -  Shift of technique to augmented urethroplasty due to any circumstance

          -  History of pelvic radiation therapy

          -  Active treatment to enhance erectile function (such as PDE5-inhibitors and
             intracavernous injections) at the moment of prescreening for inclusion in this trial

          -  Any condition or situation, which, in the investigator's opinion, puts the patient at
             significant risk, could confound the study results, or may interfere significantly
             with the patient's participation in the study

          -  Patient declares that it will be impossible for him to attend the follow-up
             consultations
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolaas Lumen, MD, PhD</last_name>
    <phone>+3293322276</phone>
    <email>nicolaas.lumen@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wesley Verla, MD</last_name>
    <phone>+32498083423</phone>
    <email>wesley.verla@uzgent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Urology, SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitriy Nikolavsky</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507-1912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Virasoro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Centro de Educación Médica e Investigaciones Clínicas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Capiel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Giudice</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Urology, Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley Verla, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolaas Lumen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Urology, University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Joniau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lujie Song</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Uretra Las Alamedas</name>
      <address>
        <city>Ciudad de mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erick Ramirez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Hospital San José Tecnológico de Monterrey, Universidad de Monterrey</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Suarez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Hospital de Santa María, Universidad de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Martins</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Hospital Universitario de Getafe</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Angulo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Urology, Hospital Univ. de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Félix Campos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamsin Greenwell</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>China</country>
    <country>Mexico</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Latini JM, McAninch JW, Brandes SB, Chung JY, Rosenstein D. SIU/ICUD Consultation On Urethral Strictures: Epidemiology, etiology, anatomy, and nomenclature of urethral stenoses, strictures, and pelvic fracture urethral disruption injuries. Urology. 2014 Mar;83(3 Suppl):S1-7. doi: 10.1016/j.urology.2013.09.009. Epub 2013 Nov 8. Review.</citation>
    <PMID>24210733</PMID>
  </reference>
  <reference>
    <citation>Palminteri E, Berdondini E, Verze P, De Nunzio C, Vitarelli A, Carmignani L. Contemporary urethral stricture characteristics in the developed world. Urology. 2013 Jan;81(1):191-6. doi: 10.1016/j.urology.2012.08.062. Epub 2012 Nov 13.</citation>
    <PMID>23153951</PMID>
  </reference>
  <reference>
    <citation>Morey AF, Watkin N, Shenfeld O, Eltahawy E, Giudice C. SIU/ICUD Consultation on Urethral Strictures: Anterior urethra--primary anastomosis. Urology. 2014 Mar;83(3 Suppl):S23-6. doi: 10.1016/j.urology.2013.11.007. Epub 2013 Dec 27. Review.</citation>
    <PMID>24373726</PMID>
  </reference>
  <reference>
    <citation>Jordan GH, Eltahawy EA, Virasoro R. The technique of vessel sparing excision and primary anastomosis for proximal bulbous urethral reconstruction. J Urol. 2007 May;177(5):1799-802.</citation>
    <PMID>17437823</PMID>
  </reference>
  <reference>
    <citation>Gur U, Jordan GH. Vessel-sparing excision and primary anastomosis (for proximal bulbar urethral strictures). BJU Int. 2008 May;101(9):1183-95. doi: 10.1111/j.1464-410X.2008.07619.x.</citation>
    <PMID>18399836</PMID>
  </reference>
  <reference>
    <citation>Lumen N, Poelaert F, Oosterlinck W, Lambert E, Decaestecker K, Tailly T, Hoebeke P, Spinoit AF. Nontransecting Anastomotic Repair in Urethral Reconstruction: Surgical and Functional Outcomes. J Urol. 2016 Dec;196(6):1679-1684. doi: 10.1016/j.juro.2016.06.016. Epub 2016 Jun 12.</citation>
    <PMID>27307398</PMID>
  </reference>
  <reference>
    <citation>Andrich DE, Mundy AR. Non-transecting anastomotic bulbar urethroplasty: a preliminary report. BJU Int. 2012 Apr;109(7):1090-4. doi: 10.1111/j.1464-410X.2011.10508.x. Epub 2011 Sep 20.</citation>
    <PMID>21933325</PMID>
  </reference>
  <reference>
    <citation>Virasoro R, Zuckerman JM, McCammon KA, DeLong JM, Tonkin JB, Capiel L, Rovegno AR, Favre G, Giudice CR, Eltahawy EA, Gur U, Jordan GH. International multi-institutional experience with the vessel-sparing technique to reconstruct the proximal bulbar urethra: mid-term results. World J Urol. 2015 Dec;33(12):2153-7. doi: 10.1007/s00345-015-1512-9. Epub 2015 Feb 18.</citation>
    <PMID>25690318</PMID>
  </reference>
  <reference>
    <citation>Bugeja S, Andrich DE, Mundy AR. Non-transecting bulbar urethroplasty. Transl Androl Urol. 2015 Feb;4(1):41-50. doi: 10.3978/j.issn.2223-4683.2015.01.07. Review.</citation>
    <PMID>26816808</PMID>
  </reference>
  <reference>
    <citation>Anderson KM, Blakely SA, O'Donnell CI, Nikolavsky D, Flynn BJ. Primary non-transecting bulbar urethroplasty long-term success rates are similar to transecting urethroplasty. Int Urol Nephrol. 2017 Jan;49(1):83-88. doi: 10.1007/s11255-016-1454-1. Epub 2016 Nov 14.</citation>
    <PMID>27844407</PMID>
  </reference>
  <reference>
    <citation>Le W, Li C, Zhang J, Wu D, Liu B. Preliminary clinical study on non-transecting anastomotic bulbomembranous urethroplasty. Front Med. 2017 Jun;11(2):277-283. doi: 10.1007/s11684-017-0515-x. Epub 2017 Apr 22.</citation>
    <PMID>28432540</PMID>
  </reference>
  <reference>
    <citation>Andrich DE, Dunglison N, Greenwell TJ, Mundy AR. The long-term results of urethroplasty. J Urol. 2003 Jul;170(1):90-2.</citation>
    <PMID>12796652</PMID>
  </reference>
  <reference>
    <citation>Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322-30.</citation>
    <PMID>15227649</PMID>
  </reference>
  <reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </reference>
  <reference>
    <citation>Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2.</citation>
    <PMID>19638912</PMID>
  </reference>
  <reference>
    <citation>Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-30.</citation>
    <PMID>9187685</PMID>
  </reference>
  <reference>
    <citation>Utomo E, Blok BF, Pastoor H, Bangma CH, Korfage IJ. The measurement properties of the five-item International Index of Erectile Function (IIEF-5): a Dutch validation study. Andrology. 2015 Nov;3(6):1154-9. doi: 10.1111/andr.12112. Epub 2015 Oct 9.</citation>
    <PMID>26453539</PMID>
  </reference>
  <reference>
    <citation>Verla W, Waterloos M, Lumen N. Urethroplasty and Quality of Life: Psychometric Validation of a Dutch Version of the Urethral Stricture Surgery Patient Reported Outcome Measures. Urol Int. 2017;99(4):460-466. doi: 10.1159/000479189. Epub 2017 Aug 30.</citation>
    <PMID>28850951</PMID>
  </reference>
  <reference>
    <citation>Lesaffre E. Superiority, equivalence, and non-inferiority trials. Bull NYU Hosp Jt Dis. 2008;66(2):150-4.</citation>
    <PMID>18537788</PMID>
  </reference>
  <reference>
    <citation>Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005 Oct 1;23(28):7199-206.</citation>
    <PMID>16192604</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urethral stricture</keyword>
  <keyword>urethroplasty</keyword>
  <keyword>bulbar urethra</keyword>
  <keyword>reconstructive surgery</keyword>
  <keyword>lower urinary tract symptoms</keyword>
  <keyword>erectile function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Urethral Stricture</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

